Insider Trading Alert - MDSO, KAI And VVUS Traded By Insiders

Yesterday, July 6, 2016, 44 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $29.28 to $15,030,134.21.

Highlighted Stocks Traded by Insiders:

Medidata Solutions (MDSO) - FREE Research Report

Sherif Tarek, who is Chairman & CEO at Medidata Solutions, sold 7,500 shares at $46.35 on July 6, 2016. Following this transaction, the Chairman & CEO owned 899,616 shares meaning that the stake was reduced by 0.83% with the 7,500-share transaction.

The shares most recently traded at $47.34, up $0.99, or 2.09% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 17,500
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 161,886
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 161,886

The average volume for Medidata Solutions has been 347,700 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.7 billion and is part of the technology sector and computer software & services industry. Shares are down 4.75% year-to-date as of the close of trading on Wednesday.

Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 141.0. Currently, there are 8 analysts who rate Medidata Solutions a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including premium valuation, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kadant (KAI) - FREE Research Report

Tully William P, who is Director at Kadant, sold 3,750 shares at $51.85 on July 6, 2016. Following this transaction, the Director owned 5,000 shares meaning that the stake was reduced by 42.86% with the 3,750-share transaction.

The shares most recently traded at $52.45, up $0.60, or 1.15% since the insider transaction. Historical insider transactions for Kadant go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 27,500
  • 24-Week # shares sold: 27,500

The average volume for Kadant has been 65,700 shares per day over the past 30 days. Kadant has a market cap of $572.3 million and is part of the industrial goods sector and industrial industry. Shares are up 28.86% year-to-date as of the close of trading on Wednesday.

Kadant Inc. supplies equipment used in papermaking, paper recycling, and other process industries primarily in North America, China, and Europe. The company operates in two segments, Papermaking Systems and Wood Processing Systems. The stock currently has a dividend yield of 1.46%. The company has a P/E ratio of 16.8. Currently, there are 2 analysts who rate Kadant a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KAI - FREE

TheStreet Quant Ratings rates Kadant as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Kadant Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

VIVUS (VVUS) - FREE Research Report

Varghese Santosh T, who is VP, Medical & Reg Affairs at VIVUS, sold 366 shares at $1.21 on July 6, 2016. Following this transaction, the VP, Medical & Reg Affairs owned 101,525 shares meaning that the stake was reduced by 0.36% with the 366-share transaction.

The shares most recently traded at $1.19, down $0.02, or 1.68% since the insider transaction. Historical insider transactions for VIVUS go as follows:

  • 4-Week # shares bought: 3,080
  • 4-Week # shares sold: 329
  • 12-Week # shares bought: 3,080
  • 12-Week # shares sold: 329
  • 24-Week # shares bought: 3,080
  • 24-Week # shares sold: 329

The average volume for VIVUS has been 897,900 shares per day over the past 30 days. VIVUS has a market cap of $127.0 million and is part of the health care sector and drugs industry. Shares are up 12.25% year-to-date as of the close of trading on Wednesday.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. Currently, there is 1 analyst who rates VIVUS a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVUS - FREE

TheStreet Quant Ratings rates VIVUS as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and weak operating cash flow. Get the full VIVUS Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Starbucks Surprises With U.S. Sales Up 2%

Starbucks Surprises With U.S. Sales Up 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company